Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

The study group was 228 children.

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the children and staff both knew the treatment.

Groups ran in parallel: each of the children stayed in one arm throughout.

The primary endpoint was annualized HV at month 12.

What Was Measured

PubMed files the paper under topics including Body Height, Dwarfism, Pituitary, Growth Disorders, Growth Hormone, Human Growth Hormone and Recombinant Proteins.

The authors tagged it with the keywords growth hormone deficiency, long-acting growth hormone, pediatric, somatrogon and somatropin.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 228 children.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.